Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role

SALT LAKE CITY, June 16, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has named Thomas P. Slavin Jr. (T.J.), M.D., FACMG, DABMD, chief medical officer of the company. He will report directly to Nicole Lambert, president of Myriad Genetic Laboratories.

In his new role, Dr. Slavin will apply deep clinical and scientific expertise, combined with proven leadership and experience in precision medicine, to further elevate Myriad’s portfolio of genetic tests spanning oncology, women’s health and mental health. Previously, Dr. Slavin served as senior vice president of Medical Affairs for Oncology at Myriad Genetics.

“We are fortunate to have a widely recognized expert with T.J.’s credentials and ability to collaborate across healthcare, from large academic institutions to private practice groups to research organizations,” said Lambert. “T.J. has dedicated his career to helping patients benefit from genetic services. His breadth of experience in research, clinical services, and guideline committees aligns directly with our goal of making genetic testing more accessible and inclusive.”

“This is a pivotal time at Myriad Genetics and in the fast-growing field of genetic testing and precision medicine. I look forward to building on the strong foundation of best-in-class science and clinical support that have always been at the heart of Myriad and our commitment to healthcare,” said Dr. Slavin.

Dr. Slavin is triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. Prior to joining Myriad Genetics in March 2020, he served as assistant professor in the departments of Medical Oncology & Therapeutics Research and Population Sciences at City of Hope National Medical Center. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer. He also served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes.

Focused on expanding genetics education for cancer care providers, Dr. Slavin has helped shape both the American Society of Clinical Oncology’s (ASCO) University as well as City of Hope’s hereditary genomics training program. He has authored 70 publications that collectively have analyzed genomic data from over 500,000 patients.

Dr. Slavin is committed to expanding the reach and understanding of genetic testing for patients, consumers and healthcare providers. He is a sought-after speaker, thought leader and host of two popular webcasts: Inside the Genome and Oncology Live.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to elevating Myriad’s portfolio of genetic tests; making genetic testing more accessible and inclusive; and the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; risks related to our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19; the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or that we may not be able to operate our business on a profitable basis; risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; risks related to the material weakness identified in our internal control over financial reporting, including the impact thereof and our remediation plan; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Transition Report on Form 10-K for the six month transition period ended December 31, 2020, which was filed with the Securities and Exchange Commission on March 16, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.